Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cardio-metabolic effects of apremilast in psoriatic arthritis
NL-OMON43353Active, not recruiting
- Sponsor
- Reade
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of apremilast in psoriatic arthritis (PsA), sponsored by Reade. Primary endpoint: Body composition. Started Mar 2017; status: active, not recruiting.
02
Drugs
apremilast
03
Conditions
psoriatic arthritis (PsA)
Beyond the preview
Go deeper on NL-OMON43353.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON43353.